VTRS · Earnings call · 2026Q2T · Full report
Strategic Review and Divestiture
Viatris Inc · 2026-08-06 · Importance 40 · Surprise 42 · In source text
Viatris is executing an enterprise-wide strategic review intended to redirect capital, talent, and resources toward higher-growth opportunities. The company is delivering previously committed savings while reinvesting part of those savings to support growth and improve operating leverage. Viatris agreed to sell the global rights to Tyrvaya, reflecting a strategic decision to exit eye care as a therapeutic-area focus; the transaction is expected to close in the second half of 2026 subject to customary conditions. Management is also evaluating disciplined, in-market, accretive business-development opportunities and said the M&A environment remains active.
Key facts
- Viatris agreed to sell the global rights to Tyrvaya as part of strategic shift away from eye care
- Company has delivered the savings committed in the enterprise-wide strategic review and is reinvesting a portion to support future growth
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | realized | — | Company has delivered the savings committed in the enterprise-wide strategic review and is reinvesting a portion to support future growth |
| cash | negative | committed | — | Company has delivered the savings committed in the enterprise-wide strategic review and is reinvesting a portion to support future growth |